Yannick Verhoeven

Yannick Verhoeven

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Seminars in Cancer Biology
Verified
Journal Article
Open access
YVYannick Verhoeven
Yannick Verhoeven
STSam Tilborghs
Sam Tilborghs
JJJulie Jacobs
Julie Jacobs
JWJorrit De Waele
Jorrit De Waele
DQDelphine Quatannens
Delphine Quatannens
Peter Van DamPeter Van Dam
Peter Van Dam
The Signal Transducer and Activator of Transcription (STAT) family of proteins consists of transcription factors that play a complex and essential role in the regulation of physiologic cell processes, such as proliferation, differentiation, apoptosis and angiogenesis, and serves to organize the epigenetic landscape of immune cells. To date, seven STAT genes have been identified in the human genome; STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. They all account for diverse effects in response to extracellular signaling proteins, mainly by altering gene transcription in the effector cells. Members of the STAT family have been implicated in human cancer development, progression, metastasis, survival and resistance to treatment. Particularly STAT3 and STAT5 are of interest in cancer biology. They are currently considered as oncogenes, but their signaling is embedded into a complex and delicate balance between different (counteracting) transcription factors, and thus, in some contexts they can have a tumor suppressive role. Assessing STAT signaling mutations as well as screening for aberrant STAT pathway activation may have a role to predict sensitivity to immunotherapy and targeted STAT inhibition. In the present comprehensive review of the literature, we discuss in-depth the role of each STAT family member in cancer, assemble cutting-edge information on the use of these molecules as potential biomarkers and targets for treatment, and address why their clinical implementation is controversy.

1 December 2017 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
STSam Tilborghs
Sam Tilborghs
JCJerome Corthouts
Jerome Corthouts
YVYannick Verhoeven
Yannick Verhoeven
DRDavid ARIAS Arias Ron
David ARIAS Arias Ron
CRChristian Rolfo
Christian Rolfo
Peter Van DamPeter Van Dam
Peter Van Dam

1 January 2019 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
Peter Van DamPeter Van Dam
Peter Van Dam
YVYannick Verhoeven
Yannick Verhoeven
XTXuan B. Trinh
Xuan B. Trinh
AWAn Wouters
An Wouters
FLFilip Lardon
Filip Lardon
MLMartin Lammens
Martin Lammens
Binding between the receptor activator of nuclear factor-kB (RANK) and its ligand (RANKL) triggers recruitment of TNF receptor associated factor (TRAF) adaptor proteins and activation of downstream pathways. RANK/RANKL signaling is controlled by a decoy receptor called osteoprotegerin (OPG) which interacts with RANKL. Additional networks regulating RANK/RANKL signaling are active in a context specific manner. RANK/RANKL signaling is essential for the differentiation of bone-resorbing osteoclasts, and is deregulated in pathological processes such as postmenopausal osteoporosis or cancer induced bone destruction. Cells expressing RANK and RANKL are commonly found in the tumor microenvironment. The RANKL/RANK pathway is often overexpressed in tumors of the breast, prostate, endometrium, cervix, stomach, oesophagus and bladder, thyroid and correlated with poor prognosis. RANK signaling plays an important role in the innate and adaptive immune response as it generates regulatory T (Treg) cells and increases production of cytokines. RANK expression induces chemoresistance in vitro through the activation of multiple signal transduction pathways. RANKL blockade improves the efficacy of anti-CTLA-4 monoclonal antibodies against solid tumors and experimental metastases. As RANK inhibition enhances the immune response there is an increasing interest in combining it with immune therapy in an attempt to sensitize immune resistant tumors to immune therapies. Several studies are ongoing to assess this concept. The role of RANK/RANKL inhibition should be further pursued as an immunomodulatory strategy in combination with other treatment modalities.

27 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ADAndreas Domen
Andreas Domen
DQDelphine Quatannens
Delphine Quatannens
SZSara Zanivan
Sara Zanivan
CDChristophe Deben
Christophe Deben
JAJonas Van Audenaerde
Jonas Van Audenaerde
HPHans Prenen
Hans Prenen
Cancer arises from mutations accruing within cancer cells, but the tumor microenvironment (TME) is believed to be a major, often neglected, factor involved in therapy resistance and disease progression. Cancer-associated fibroblasts (CAFs) are prominent and key components of the TME in most types of solid tumors. Extensive research over the past decade revealed their ability to modulate cancer metastasis, angiogenesis, tumor mechanics, immunosuppression, and drug access through synthesis and remodeling of the extracellular matrix and production of growth factors. Thus, they are considered to impede the response to current clinical cancer therapies. Therefore, targeting CAFs to counteract these protumorigenic effects, and overcome the resistance to current therapeutic options, is an appealing and emerging strategy. In this review, we discuss how CAFs affect prognosis and response to clinical therapy and provide an overview of novel therapies involving CAF-targeting agents in lung and pancreatic cancer.

4 December 2019 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
GOGizem Oner
Gizem Oner
SASevilay Altintas
Sevilay Altintas
ZCZafer Canturk
Zafer Canturk
WTWiebren Tjalma
Wiebren Tjalma
YVYannick Verhoeven
Yannick Verhoeven
PDPeter A. Dam
Peter A. Dam

Verified
Journal Article
Open access
PDF file
Peter Van DamPeter Van Dam
Peter Van Dam
YVYannick Verhoeven
Yannick Verhoeven
JJJulie Jacobs
Julie Jacobs
AWAn Wouters
An Wouters
WTWiebren Tjalma
Wiebren Tjalma
XTXuan Bich Trinh
Xuan Bich Trinh
RANK ligand (RANKL) is a member of the tumor necrosis factor alpha superfamily of cytokines. It is the only known ligand binding to a membrane receptor named receptor activator of nuclear factor-kappa B (RANK), thereby triggering recruitment of tumor necrosis factor (TNF) receptor associated factor (TRAF) adaptor proteins and activation of downstream pathways. RANK/RANKL signaling is controlled by a decoy receptor called osteoprotegerin (OPG), but also has additional more complex levels of regulation. The existing literature on RANK/RANKL signaling in cervical cancer was reviewed, particularly focusing on the effects on the microenvironment. RANKL and RANK are frequently co-expressed in cervical cancer cells lines and in carcinoma of the uterine cervix. RANKL and OPG expression strongly increases during cervical cancer progression. RANKL is directly secreted by cervical cancer cells, which may be a mechanism they use to create an immune suppressive environment. RANKL induces expression of multiple activating cytokines by dendritic cells. High RANK mRNA levels and high immunohistochemical OPG expression are significantly correlated with high clinical stage, tumor grade, presence of lymph node metastases, and poor overall survival. Inhibition of RANKL signaling has a direct effect on tumor cell proliferation and behavior, but also alters the microenvironment. Abundant circumstantial evidence suggests that RANKL inhibition may (partially) reverse an immunosuppressive status. The use of denosumab, a monoclonal antibody directed to RANKL, as an immunomodulatory strategy is an attractive concept which should be further explored in combination with immune therapy in patients with cervical cancer.